logo-loader

NA Proactive news snapshot: CytoDyn, Mandalay Resources, CleanSpark, Duos Technologies, Quantum Computing - UPDATE

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Newspapers and laptop
Your daily round-up from the world of Proactive

Duos Technologies Group Inc (NASDAQ:DUOT) has raised a further $1.06 million in net proceeds after an over-allotment was exercised on the previously announced public offering, it said Friday. On February 13, the analytical technology solutions group, said it had offered 1.3 million shares at $6 a thow in the $8 million raise.Today, the group said the underwriters had partially exercised and closed on their over-allotment option and bought an additional 192,188 shares at $6 each. Duos intends to use the net proceeds for research and development activities, sales and marketing, and for general working capital

Quantum Computing Inc (OTCMKTS:QUBT) is adding key medical expertise to its technical advisory board. The Leesburg, Virginia-based technology firm said Dr Michael Liebman is joining its advisory board to add a “unique perspective” that will allow the company to apply its techniques to the pharmaceutical and healthcare sectors. Liebman’s research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective.

CytoDyn Inc (OTCMKTS:CYDY) announced Friday it will begin its Phase 2 clinical trial of leronlimab (PRO 140) for the treatment of about 22 different solid tumor cancers.  In a statement, the company said it is launching the second study after receiving Institutional Review Board (IRB) approval to target melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other cancers.

Mandalay Resources Corp (TSE:MND) (OTCMKTS:MNDJF) told investors that full-year 2019 was 'challenging' but the fourth quarter to end December saw significant improvement as grades improved and production was boosted. The metals miner operates mines in Sweden (Björkdal) and Australia (Costerfield) and produces gold, silver and antimony.

CleanSpark Inc (NASDAQ:CLSK) put out a statement after the bell Thursday, informing investors that it had no material information as to why its share price moved more than usual during trading. The energy software and technology company, which uplisted to the Nasdaq in January, saw its second-highest trading volume of the month, and shares dipped 11%, but the company insists there is no clear reason for a decline. 

Agile Therapeutics Inc (NASDAQ:AGRX), which is preparing to commercialize its lead product Twirla, announced Friday the pricing of its underwritten public offering that’s expected to raise about $45 million. The Princeton, New Jersey-based women’s health company is offering 15 million shares of its common stock at a price of $3 per share -- which closed at $3.58 on Thursday. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The FDA recently approved Twirla, a low-dose prescription contraceptive delivered through the skin. 

Antibe Therapeutics Inc. (CVE:ATE) (OTCMKTS:ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50 company for the second consecutive year, in recognition of its performance on the TSX Venture Exchange. Dan Legault, Antibe’s CEO commented: "It’s exciting to be recognized as a TSX Venture top performer for the second year in a row. We believe this award reflects a growing awareness of the best-in-class potential of our drug pipeline,” He added: "We hope to continue this success for our shareholders, as we complete our lead drug’s final Phase 2 trial, expand partnering activities and evolve into a Phase 3 company. We look forward to reaching a growing audience of institutional and retail investors in the coming year.”

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced that it will report its fourth-quarter and full-year 2019 financial and operating results after the close of US financial markets on Thursday, February 27, 2020. In addition, the group said its management will host a conference call to provide an update on corporate activities and discuss the quarterly and full-year financial results.

Thunderbird Entertainment Group Inc. (CVE:TBRD) (OTCMKTS:THBRF), a global, multiplatform entertainment company with offices in Los Angeles, Vancouver, Ottawa and Toronto, said it will hold a conference call and webcast to share the Company's second quarter 2020 financial results on Monday, March 2, 2020 at 6am PST/9am EST.

Metalla Royalty & Streaming Ltd. (CVE:MTA) (NYSEAMERICAN:MTA) said its board of directors has approved and declared a monthly cash dividend payment of CAD $0.004 per share for March, April, and May 2020, on its common shares, subject to any applicable tax withholding obligations).

Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) said it has granted an aggregate of 175,000 stock options to directors, officers and consultants of the corporation under its stock option plan, at an exercise price of $0.22 per common share and expiring five years from the date of grant.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 5 hours ago

5 min read